Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial

Anakinra and tocilizumab are used for severe Covid-19, but only one previous randomized controlled trial (RCT) has studied both. We performed a multi-center RCT comparing anakinra or tocilizumab versus usual care (UC) for adults at high risk of deterioration. The study was conducted June 2020 to Mar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2023, Vol.18 (12), p.e0295838-e0295838
Hauptverfasser:	Sundén-Cullberg, Jonas, Chen, Puran, Häbel, Henrike, Skorup, Paul, Janols, Helena, Rasmuson, Johan, Niward, Katarina, Östholm Balkhed, Åse, Chatzidionysiou, Katerina, Asgeirsson, Hilmir, Blennow, Ola, Parke, Åsa, Svensson, Anna-Karin, Muvva, Jagadeeswara Rao, Ljunggren, Hans-Gustav, Horne, Anna-Carin, Ådén, Ulrika, Henter, Jan-Inge, Sönnerborg, Anders, Vesterbacka, Jan, Nowak, Piotr, Lampa, Jon
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiarthritic agents Antibiotics Care and treatment COVID-19 COVID-19 Drug Treatment Disease prevention Drug dosages Ferritin Hospital patients Hospitalization Hospitals Humans Infections Interleukin 1 receptor antagonist Interleukin 1 Receptor Antagonist Protein - adverse effects L-Lactate dehydrogenase Labels Lactate dehydrogenase Lymphocytes Monoclonal antibodies Oxygen Oxygen content Patients SARS-CoV-2 Statistical analysis Treatment Outcome Ventilators
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!